Head & Neck Cancer

A five-year lesson in cancer, worry and hope.

The Food and Drug Administration granted a priority review to the supplemental biologics license application for Keytruda (pembrolizumab) for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

A recent meta-analysis has found no noticeable difference in immunotherapy’s efficacy based on patient sex.

Survivor diagnosed with second cancer after surgeon spots a lump on her throat while watching TV.

Immunotherapy may lead to a major change in how the treatment of metastatic recurrent head and neck cancer is approached, according to Barbara Burtness, M.D., a professor of medicine at Yale School of Medicine.

Despite associated toxicities, cisplatin chemotherapy induced superior efficacy compared with a new alternative among patients with HPV-positive oropharyngeal carcinoma.

The FDA has granted an accelerated approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

Patients who received chemotherapy, actively smoked and drank alcohol, and were diagnosed with head and neck cancer reported significantly higher rates of opiate use, according to study results presented at the American Society of Clinical Oncology (ASCO) 2018 Palliative and Supportive Care Symposium.

SCOTT WIESKAMP KNEW THE spot on his tonsil wasn’t normal.

Patients with head and neck cancer appeared to be receptive to lung cancer screening, according to recent research performed at the University of Iowa Hospitals and Clinics.

To combat the psychological effects from a lymphedema diagnosis, patients need to be equipped with the knowledge and understanding of what the condition is and how it is treated.

The Food and Drug Administration has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options, according to a statement from Loxo Oncology, the developer of the selective RET inhibitor.

Patients with cancer are 10 times less likely to have an opioid-associated death, according to recent research conducted at Duke University.

Immunotherapy pioneers James P. Allison and Dr. Tasuku Honjo have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

The mouth is also part of the body, and yet, it is only in the past few years that oncologists have begun recommending patients see a dentist before they begin treatment to be sure the teeth and gums are in good shape.

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.

From genetic mutations to treatment behind bars, here's a roundup of our 2018 Summer issue.

In this week’s episode of CURE Talks Cancer, we spoke with Voigt about how he noticed a lump in a woman’s neck while watching tv and utilized the power of social media to find her – which ultimately led to a thyroid cancer diagnosis.

About 40 percent of people with cancer are of working age, and typically have a need to maintain their employment throughout their treatment.

Instead of undergoing surgery for potential cancer, many people with thyroid nodules can safely opt for surveillance.

Proper oral care is vital during cancer treatment, explains a dental hygienist who specialized in dental oncology.

While head and neck cancer is more common in men than in women, women may actually be less likely to receive aggressive treatment for the disease, which could affect outcomes.

The majority of adolescent and young adult (AYA) patients who are diagnosed with cancer are expected to live past the five-year mark, though survival and health outcomes seem to differ by disease type, according to recent research published in the journal Cancer.

While having a career as a flight attendant allows individuals to travel the globe, exposure to carcinogens and frequent disruptions in circadian rhythms may increase cancer prevalence in these individuals, according to recent research published in the journal Environmental Health.

Because little is known about the effect of patients' sex on the efficacy of immune checkpoint inhibitors as cancer treatments, the researchers performed a systematic review and meta-analysis to determine the heterogeneity of immune checkpoint inhibitor efficacy between men and women.

In a presentation at the 2018 ASCO Annual Meeting, researchers from Kaiser Permanente also found that women were almost twice as likely to die from the disease compared with non-cancer deaths.

John Mahoney, famous for playing Mar- tin Crane, father of the title character on the TV show “Frasier,” died of throat cancer on Feb. 4 while in hospice care, according to the Chicago Tribune.

Cancer survivors worry about recurrence, but seldom think about their risk for new primaries.